Science & health
Personalised melanoma vaccine cuts recurrence and spread risk in major clinical trial
A personalised mRNA vaccine given with Keytruda reduced the combined risk of melanoma returning or patients dying by 42% over two years, while the risk of the cancer spreading fell 38% compared with immunotherapy alone. The trial involved 1,137 adults whose tumours had been removed. Researchers and independent experts call the results an important proof of principle, but longer follow-up is needed to establish an overall-survival benefit. The findings have not yet appeared in a peer-reviewed medical journal, and personalised production could make widespread use costly.
Editorial summary · Publisher article
What matters
- The vaccine was tailored to each patient using genetic information from their tumour.
- About two-thirds of participants received the vaccine alongside Keytruda; the remainder received a placebo.
- The trial is continuing to assess long-term recurrence and survival outcomes.
- MSD and Moderna are testing the approach against kidney, bladder and lung cancers.
Evidence remains incomplete
Experts described the results as impressive but cautioned that a single melanoma trial cannot establish whether the approach works across cancers or improves average lifespan. Full results are due at a medical conference before peer-reviewed publication.
Context & caveats
- The reported results are interim and have not yet been independently scrutinised through peer review.
Why this made the edition
A substantial clinical-trial report with independent expert caveats, patient numbers, outcome measures and access considerations. The findings remain preliminary because follow-up is short and full results are not yet peer-reviewed.
Source material